Key result
Continuous cyclic peritoneal dialysis in 14 patients demonstrated a low peritonitis rate (1 per 42 patient-months) and satisfactory clearances (e.g., Curea 67 L/wk).
Why the study?
Does continuous cyclic peritoneal dialysis (CCPD) reduce peritonitis and maintain adequate clearance compared to CAPD in dialysis patients?
Observational (n=14)
Does continuous cyclic peritoneal dialysis (CCPD) reduce peritonitis and maintain adequate clearance compared to CAPD in dialysis patients?
CCPD is a viable alternative to CAPD that may reduce peritonitis rates while maintaining excellent clearance and ultrafiltration.
Continuous cyclic peritoneal dialysis (CCPD) was designed to reduce the high incidence of peritonitis and eliminate the multiple interruption created by dialysis exchanges during the day needed for CAPD, while maintaining the quality of dialysis. Three nocturnal cycles with 2 liters of dialysate lasting 3 hours each are provided by an automated cycler while the patient sleeps. Two liters are left in the abdomen in the morning. Only one daily connection and one disconnection are required between the peritoneal catheter and the cycler line. Our 84 patient months experience with 14 patients reveals a low incidence of peritonitis (1 per 42 patient months), satisfactory ultrafiltration rates and clearances that compare favorably with those of CAPD (Curea 67, Ccreatinine 58, and CB12 45 L/wk). Blood pressure control has been excellent while most patients enjoy liberal diets. This preliminary study suggests that CCPD may indeed reduce the rate of peritonitis, provide excellent clearance and ultrafiltration, allow more free time to the patient and maintain a steady physiological state.
No takes yet. Share an insight, caveat, or question.
Díaz-Buxó et al. (1981) conducted an observational in End-stage renal disease requiring dialysis (n=14). Continuous cyclic peritoneal dialysis (CCPD) was evaluated on Incidence of peritonitis and clearances. Continuous cyclic peritoneal dialysis in 14 patients demonstrated a low peritonitis rate (1 per 42 patient-months) and satisfactory clearances (e.g., Curea 67 L/wk).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: